SecBot SecBot
8-K ·Filed May 4, 2026

CABA

Cabaletta Bio, Inc.
BEARISH
Impact 7/10
Horizonimmediate Processed6mo ago SEC0001193125-26-202446
8-K material event: Items 1.01
Actionable Insight ▼ Bearish

The massive ~51% dilution from this offering will pressure the stock near-term. Monitor the stock for potential further downside as the market absorbs the new shares. The cash runway extension into mid-2027 is positive for the pipeline, but the dilution overhang and lack of near-term revenue catalysts suggest continued weakness.

DirectionBearish
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$3.83
T+0 close · May 4, 2026 · via day close
Latest settled
−31.59%
T+60 · $2.62
Vs SPY
−33.45%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 4 $3.83entry
  2. T+1 · 7mo ago +8.36%α +7.56% · $4.15
  3. T+5 · 6mo ago −0.26%α −3.20% · $3.82
  4. T+20 · 6mo ago −4.18%α −9.82% · $3.67
  5. T+60 · 4mo ago −31.59%α −33.45% · $2.62
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Cabaletta Bio priced a $150M underwritten offering of 51.7M shares at $2.90/share, representing ~51% dilution from the prior ~100.5M shares outstanding. The filing also disclosed a preliminary cash balance of ~$117M as of March 31, 2026, and the company reported Q4 2025 EPS of -$0.40, a 3.1% miss vs consensus of -$0.39. The capital raise extends the cash runway into mid-2027 to fund clinical development of rese-cel, but the massive dilution and lack of revenue fundamentally overshadow the pipeline progress.

Key Financial Metrics

EPS
−$0.40
est −$0.39 · -2.6%
Rating
miss
Deal Value
$150.0M

Key Facts

  • Priced underwritten offering of 51,725,000 shares at $2.90 per share, raising ~$150M in gross proceeds (~$141M net)
  • Offering represents ~51% increase in shares outstanding from ~100.5M to ~152.2M shares
  • Q4 2025 EPS of -$0.40 missed consensus of -$0.39 by 3.1%
  • Preliminary cash balance of ~$117M as of March 31, 2026
  • Net proceeds extend cash runway into mid-2027 for rese-cel clinical development and manufacturing scale-up
  • No revenue reported; company is a pre-commercial biotechnology firm

Financial Impact

~$141M net proceeds from offering; ~51% dilution; Q4 2025 net loss of $41.9M

dilutioncash runwayeps

Risk Factors

  • Immediate and significant dilution of ~51% from the offering
  • No revenue and ongoing operating losses; net loss of $167.9M in FY2025
  • Clinical-stage risk; rese-cel may fail in pivotal trials or face regulatory delays
  • Cash runway only into mid-2027; may require additional capital before reaching profitability

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
81% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 9 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-202446
Document: d145767dex992.htm0001193125-26-202446
Document: d145767d8k.htm0001193125-26-202446
Document: d145767dex991.htm0001193125-26-202446
Document: d145767dex51.htm0001193125-26-202446
Document: 0001193125-26-202446-index-headers.html0001193125-26-202446
Document: 0001193125-26-202446-index.html0001193125-26-202446
Document: 0001193125-26-202446.txt0001193125-26-202446
8-K Data (Synthetic)0001193125-26-202446

Track record

29 reports on CABA

Performance horizon

3 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +31.59% at T+60 after the May 4, 2026 report. 4 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $1.15 Now $1.11 −3.09% settles Nov 23
  2. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.32 Now $1.11 −15.91% settles Nov 23
  3. Nov 12, 20264d ago SC 13G/A Neutral 2/10 Entry $1.33 Now $1.11 −16.54% settles Nov 19
  4. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $1.45 Now $1.11 −23.45% settles Nov 17
  5. Nov 9, 20267d ago 8-K Bullish 6/10 Entry $1.50 to $1.11 Now $1.11 −26.00% ▼ −26.00% −24.31% vs SPY
  6. Nov 8, 20268d ago Press Release Bullish 6/10 Entry $1.50 to $1.11 Now $1.11 −26.00% ▼ −26.00% −24.31% vs SPY
  7. Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $1.30 to $1.28 Now $1.11 −14.62% ▼ −1.54% −4.13% vs SPY
  8. Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $1.30 to $1.28 Now $1.11 −14.62% ▼ −1.54% −4.13% vs SPY
  9. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $1.28 to $1.33 Now $1.11 −13.28% ▲ +3.91% +0.62% vs SPY
  10. Nov 5, 202611d ago Press Release Neutral 4/10 No price data
Showing 10 of 29

US Market Status

Market Closed · Opens in 6h 39m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 4, 2026